Abstract Introduction: Gastrointestinal lymphoma (GIL) is the most common extranodal form of non-Hodgkin's lymphoma (NHL) with geographical and age variation of its various subtypes. Aim: To study GIL in Gharbiah, Egypt and to recognize the treatments employed and their outcomes including survival. Methods: This is a retrospective study. Between 2000 and 2002, 40 adult patients with GIL were identified in the Gharbiah population based cancer registry (GPBCR); 26 cases of whom were treated at Tanta Cancer Center (TCC). Results: GIL in Gharbiah, Egypt represented 6.2% of all GIT cancers. The median age was 47 years with slight male predominance. The commonest primary site was the stomach followed by the colon/rectum then the small intestine (67.5%, 25% and 7.5%, respectively). The commonest histological subtypes were the diffuse large B-cell (41.5%) followed by marginal zone B-cell (39%). The commonest symptoms were abdominal pains followed by vomiting. Only 18% of GILs were surgically resected. Most patients (77%) received chemotherapy with a 60% complete response (CR) rate. Once in CR, relapses are occasional. The median overall survival (OS) and progression free survival (PFS) were 31 and 14 months (95% CI, 13.2-48.7 and 6.4-21.6 months, respectively). Gastric primary site and diffuse large B cell subtype carry a non-significant worse OS and PFS than those of other sites and subtypes. 
Introduction
Gastrointestinal tract is the most common extranodal site involved by lymphoma accounting for 5%-20% of all cases [1, 2] . However, primary gastrointestinal lymphoma (GIL) is very rare, constituting only about 1%-4% of all gastrointestinal malignancies. Although lymphoma can involve any part of the gastrointestinal tract, the most frequent sites among adults are the stomach followed by the small intestine and ileocecal region [3] . In the pediatric age group, small and large intestines are the most frequent sites [4] . Diffuse large B-cell (DLBC) lymphoma is the most common pathological subtype in all sites of the gastrointestinal tract. Nevertheless, the frequency of other subtypes has recently increased in certain regions of the world [3] .
GILs can be associated with chronic inflammation that forms the basis of understanding the mucosa associated lymphoid tissue (MALT) lymphomas. However, chronic inflammation can also pose diagnostic difficulties [5, 6] . While chronic gastritis due to Helicobacter pylori is the best-studied precursor of MALT lymphoma, other parts of the GIT demonstrate precursor inflammatory lesions that lead to specific types of lymphoma [7] .
The diagnostic difficulties for GILs are compounded by the fact that often only small biopsies are available for examination and the morphology of a particular type of lymphoma may differ in the GIT compared to the lymph node. Several recent large series describing the epidemiological and clinicopathological features of primary GIT lymphomas have been published [3, [8] [9] [10] [11] [12] [13] [14] . The advent of wireless capsule endoscopy and double balloon enteroscopy has made previously inaccessible portions of GIT visible and changed our perceptions about some types of GILs. Finally, the increasing number of immunosuppressed patients (either due to HIV or iatrogenic) is associated with increasing incidence of some types of GILs that were very rarely seen previously [15] [16] [17] [18] .
Staging of GILs is a matter of debate due to various available staging systems. Although the modified Ann Arbor classification is feasible and relevant for prognosis, certain demerits in terms of disseminated and incurable infiltration of the GIT prompted development of the Paris staging system, which can differentiate distant lymphoma manifestations depending on the involved organ (using endoscopic ultrasound), and further subdivide lymph node involvement [19] .
In this retrospective study, we reviewed the clinicopathologic characteristics and treatment outcomes of 40 adult patients with GIL identified at the Gharbiah population based cancer registry (GPBCR) in Egypt.
Methods
This is a retrospective study. Patients with GILs were identified through GPBCR. Data on age, sex, sub-site, histology, grade, stage and treating center were obtained from the registry. Further data on complaints, comorbidities, treatment modalities (surgery, radiotherapy and chemotherapy), response to therapy, dates of diagnosis, surgery and relapse; and survival were obtained for that subset of patients treated at Tanta Cancer Center (TCC). The study was approved by the IRB of the Egyptian National Cancer Institute.
Inclusion criteria were patients with GIL (site codes) and a malignant histology [histology codes (ICD-O-3)] between 2000 and 2002. Exclusion criteria were non-confirmed histologic subtype as those diagnosed based on death certificate, radiology or malignant neoplasm unspecified.
Between 2000 and 2002, 42 cases with GILs contained in GPBCR were identified. Two cases were excluded; one diagnosed from death certificate and another had the diagnosis of NHL with no subtype identified. Patients' files were reviewed for clinical and pathologic data, details of treatments and their outcome including response and survival.
Statistical analysis
All analyses were done using SPSSÒ software program version 15 (Chicago, USA). Nominal and categorical data were compared for different histologies (Diffuse large B vs. others) and subsites (gastric vs. others) using the Chi squared test or Fisher's exact test. Survival was calculated using the Kaplan Meier method and groups were compared using the Log-rank test. A probability (p) < 0.05 (two sided) was considered statistically significant.
Results

GPBCR patients
GILs represented 6.2% of GIT cancers in GPBCR. All GILs were of the non-Hodgkin's lymphoma (NHL) type. The median age was 47 years (range, 20-77 years) with slight male predominance (male to female ratio of 1.2:1). The stomach was the commonest involved site followed by the colon/rectum and small intestine (67.5%, 25% and 7.5%, respectively). The gastric antrum and the cecum were the commonest subsites. Most patients (29/40) had either local or regional disease. Seven patients had a widespread disease to the liver (2 cases), lungs (2 cases), bone (1 case) or unknown sites (2 cases). Diffuse large B-cell (DLBC) subtype was the commonest subtype (41.5%) followed by the marginal-zone B-cell (MZ) subtype (39%). Other subtypes included diffuse mixed small and large cell (3 cases), B-cell Small lymphocytic (2 cases), mantel cell (1 case) and follicular (1 case). Most DLBC (11/17) and MZ (13/ 16) were located in the stomach. Table 1 shows the characteristics of the 40 GIL patients identified through GPBCR.
Tanta Cancer Center (TCC) patients
We could identify 26 cases treated at TCC, the main oncology center in Gharbiah governorate, Egypt. Their characteristics were similar to the larger GPBCR group and non-TCC cases (shown in Table 1 ). Unfortunately, clinical data particularly pertaining to treatments and follow up were not contained in GPBCR. Thus, we tried to further track as many cases as possible through reviewing cases that presented to TCC. Most patents had symptoms related to their disease with abdominal pains being the commonest (Table 2) . Only four patients underwent surgery and none received radiotherapy. More than three quarters (21/26) of patients received chemotherapy. Chemotherapy regimens used were CHOP in 14/21 patients and CVP in 7/21 patients. The median number of cycles was 6 (range, 2-8). Twelve patients (57%) had a complete remission (CR), seven had less than CR and the response was not ascertained in two patients (Table 2) . At the last visit, 10 patients were in maintained CR, 12 patients had evidence of disease progression and two patients had documented relapses that were local in one patient and distant in the other. The relapse free survival (RFS) ranged between 14 and 100 months and the median was not reached. RFS at 16 months was 71.4% (SE, 17.1%).
The median follow-up period was 76 months (range, 1-104 months). At the last documented visit, 12 patients were alive; 10 were free of lymphoma and two with evidence of lymphoma. Meanwhile, 14 patients were dead. Deaths were disease related in 11 cases. The median overall survival (OS) was 31 months (95% CI, 13.2-48.7 months) (Fig. 1) . The median progression free survival (PFS) was 14 months (95% CI, 6.4-21.6 months) (Fig. 2) .
OS and PFS according to various clinico-pathological features are shown in Table 3 . For different histological subtypes, the median OS of BLBC GIL was 10 months compared to 64 months in MZ GIL (p = 0.57). The median PFS of BLBC GIL was 6 months compared to 16 months in MZ GIL (p = 0.42). For different sites, the median OS of gastric site was 26 months compared to 31 months in intestinal sites (p = 0.57). The median PFS of gastric site was 10 months 
Discussion
In our series, GILs represented a minority of all GIT cancers (6.2%), which is comparable to an incidence of 4% reported by the literature [20] [21] [22] . Males were slightly more affected than females in our study with a male to female ratio of 1 The median age of patients in our study was 47 years. This age was relatively younger than that shown in 2 studies from China reporting a median age of 53 years [26, 28] ; and of 56 years in Singapore [29] . Other studies revealed younger age of patients e.g. mean age 21 and 34 years in two studies from India respectively [20, 25] and of 35 years in Saudi Arabia [30] reflecting the variable geographic characteristics of the disease. H. pylori infection, immunosuppression after solid-organ transplantation, celiac disease, inflammatory bowel disease, and human immunodeficiency virus (HIV) infection may be risk factors for GILs [21] . Given the retrospective nature of the current study, data on these risk factors especially H. pylori infection were not documented.
The commonest symptoms in our series were abdominal pains (46%) followed by vomiting (27%), similar to common symptoms reported by other studies [25, 27, [31] [32] [33] [34] .
A difference in prognosis and distribution of GILs has been reported in Western and Middle Eastern countries. GILs were reported to be located more frequently in the stomach in the West, but more frequently in the small intestine in the East, although this was shown to be contrary in the recent years. Increased incidence of GIL in the small intestine was thought to be due to higher incidence of immunoproliferative small intestinal disease in the Middle East [35] . Stomach is the commonest involved site in our study (69%). This finding is comparable to most studies of GILs [8, [26] [27] [28] [29] 31, 36, 37] reporting gastric involvement that ranges between 56% and 81%. Series from Jordon [38] ; Kuwait [39] and Nigeria [40] reported higher prevalence of small intestinal GILs. However, other investigators from the Middle East i.e. Saudi Arabia, reported involvement of gastric site in 51% of patients [30] . Unlike Cirillio et al. [37] and Koniaris et al. [41] , our large intestine GILs (27%) exceeded those of the small intestine (4%). Our low figures of small intestinal GILs are mainly because of exclusion of pediatric patients where intestinal GILs predominate [42, 43] . This may also be a random variation associated with a relatively low number of cases.
Similar to most studies, diffuse large B-cell (DLBC) NHL was the commonest subtype followed by marginal zone (MZ) NHL [26] [27] 29, 44] . In Japan, MZ subtype slightly exceeded DLBC subtype [8] and this may reflect the geographic variation [33] .
Similar to many studies [28] [29] 31] , most patients (81%) of the current study received chemotherapy. However, surgery was less encountered in our study (16%) and this may reflect temporal evolution of the treatment of GILs with a decreasing role of surgery and increasing that of radiation therapy and systemic therapy [8] . The complete response (CR) rate after chemotherapy in our series was 57% which is comparable to Figure 1 Overall survival of the 26 patients with gastrointestinal NHL treated at Tanta Cancer Center (TCC).
that seen in other studies [28] [29] 32, 45] reporting CR rates that range between 52% and 67%.
In our study, the median OS and PFS rates were 31 and 14 months respectively; and the two-year OS and PFS rates were 56% and 41% respectively. Survival rates in the current study were similar to those reported by many studies [29, [32] [33] [45] [46] . Higher 2-year OS (67%) was reported in a study from Singapore [29] . Also, Cirillio et al. [37] reported a median OS of 54 months, with 46% of patients surviving at 5 years. Liang et al. [28] reported the experience in the management of 425 Chinese patients with primary GILs in Hong Kong over a period of 18 years. The OS of all patients was 45% at 5 years. Multivariate analysis revealed that age below 60 years, low grade histology, stage I or II disease and absence of bulky tumor were independent prognostic factors predicting better OS. Similar to several studies [28, 46, 47] , MZ subtype had a better prognosis than other subtypes included in our study particularly DLBC.
In our study, gastric involvement had a better OS and PFS than intestinal involvement. However, the difference did not reach statistical significance. In a 15-year review of 75 cases of GILs from North India and after a mean follow-up of 4 years, the 5-year OS rates were 34%, 25% and 16% for stages I, II, or >II, respectively. The survival rate was significantly better for gastric location (44%) compared to other sites (24%) (p < 0.01) [25] . The 30-year experience of primary GILs (49 cases) at the Cancer Institute, Madras, India revealed that 5-year OS and DFS rates were 47% and 40%, respectively. There was no overall significant difference in survival between the different treatment groups. Stage, extent of surgical resection, response to treatment, serosal involvement, multimodality treatment, and performance status were significant prognostic factors. Achievement of complete remission and complete surgical resection were the most favorable independent prognostic factors on multivariate analyses [45] . In a study of the 185 patients with primary GILs from Saudi Arabia, patients with intestinal lymphoma had a 10-year survival rate of 48% comparable to 53% in those with gastric lymphoma (p = 0.431) [30] .
Our study has strengths and limitations. To the best our knowledge, it is the first study from Egypt that addresses the issue of GILs on the population level. The retrospective nature implies some missing data as these data were originally collected for reasons other than research. Moreover, the medical service in Egypt is spanned among many providers like the ministry of health, military, educational as well as private hospitals making accessibility to complete patients' information in all of these settings a difficult task. However, the study accurately reflects the practice of the oncology community within the jurisdictions of the study.
In conclusions, in our trial, GIT NHL represents 6.2% of all GIT cancers. The median age is 47 years with slight male predominance. The commonest primary site is the stomach followed by the colon/rectum. The commonest histological subtype is Marginal zone B-cell followed by the diffuse large B-cell. Most patients are treated with chemotherapy that gives 60% complete response rate. Once in CR, relapses are occasional. The median OS and PFS are relatively short as 31 and 14 months, respectively. Gastric primary site and diffuse large B cell subtype carry a non-significant worse OS and PFS that other sites and subtypes. Better classification of the primary GILs and more refined stratification of the patients according to the prognostic variables may allow individualization of treatment. Prospective studies are essential to define the underlying causative or risk factors as well as the relative roles of surgery, chemotherapy and radiotherapy.
